In the latest session, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $43.57 up 0.30% from its previous closing price of $43.44. In other words, the price has increased by $+0.13 from its previous closing price. On the day, 806402 shares were traded.
Ratios:
For a deeper understanding of Kymera Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.73 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
BofA Securities Downgraded its Buy to Neutral on January 03, 2024, whereas the target price for the stock was revised from $45 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 21 when Albers Jeffrey W. sold 4,385 shares for $39.05 per share. The transaction valued at 171,227 led to the insider holds 0 shares of the business.
Albers Jeffrey W. sold 615 shares of KYMR for $24,031 on Feb 20. The Director now owns 0 shares after completing the transaction at $39.07 per share. On Feb 09, another insider, Gollob Jared, who serves as the Chief Medical Officer of the company, sold 46,137 shares for $35.50 each. As a result, the insider received 1,638,071 and left with 74,709 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2.66B and an Enterprise Value of 2.37B. For the stock, the TTM Price-to-Sale (P/S) ratio is 33.88 while its Price-to-Book (P/B) ratio in mrq is 6.13. Its current Enterprise Value per Revenue stands at 30.19 whereas that against EBITDA is -16.57.
Stock Price History:
Over the past 52 weeks, KYMR has reached a high of $44.55, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 30.74, while the 200-Day Moving Average is calculated to be 22.91.
Shares Statistics:
For the past three months, KYMR has traded an average of 913.27K shares per day and 710.59k over the past ten days. A total of 55.59M shares are outstanding, with a floating share count of 53.55M. Insiders hold about 12.38% of the company’s shares, while institutions hold 90.16% stake in the company. Shares short for KYMR as of Jan 31, 2024 were 8.26M with a Short Ratio of 9.04, compared to 9.06M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 13.91% and a Short% of Float of 15.64%.
Earnings Estimates
There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.87, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.47 and low estimates of -$1.04.
Analysts are recommending an EPS of between -$1.64 and -$4.16 for the fiscal current year, implying an average EPS of -$3.17. EPS for the following year is -$3.19, with 14 analysts recommending between -$1.91 and -$4.56.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $15.25M this quarter.It ranges from a high estimate of $23M to a low estimate of $10M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $9.47M, an estimated increase of 61.10% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $11.36M, a decrease of -19.20% less than the figure of $61.10% in the same quarter last year. There is a high estimate of $26.9M for the next quarter, whereas the lowest estimate is $200k.
A total of 17 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $125M, while the lowest revenue estimate was $15.2M, resulting in an average revenue estimate of $53.61M. In the same quarter a year ago, actual revenue was $78.59M, down -31.80% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $72.66M in the next fiscal year. The high estimate is $129.1M and the low estimate is $20M. The average revenue growth estimate for next year is up 35.50% from the average revenue estimate for this year.
